Does CILTACABTAGENE AUTOLEUCEL Cause Second primary malignancy? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Second primary malignancy have been filed in association with CILTACABTAGENE AUTOLEUCEL (CARVYKTI). This represents 0.1% of all adverse event reports for CILTACABTAGENE AUTOLEUCEL.
5
Reports of Second primary malignancy with CILTACABTAGENE AUTOLEUCEL
0.1%
of all CILTACABTAGENE AUTOLEUCEL reports
3
Deaths
1
Hospitalizations
How Dangerous Is Second primary malignancy From CILTACABTAGENE AUTOLEUCEL?
Of the 5 reports, 3 (60.0%) resulted in death, 1 (20.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CILTACABTAGENE AUTOLEUCEL. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does CILTACABTAGENE AUTOLEUCEL Cause?
Cytokine release syndrome (570)
Pyrexia (242)
Immune effector cell-associated neurotoxicity syndrome (232)
Parkinsonism (209)
Hospitalisation (193)
Adverse event (143)
Neurotoxicity (140)
Death (130)
Malaise (126)
Fatigue (123)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which CILTACABTAGENE AUTOLEUCEL Alternatives Have Lower Second primary malignancy Risk?
CILTACABTAGENE AUTOLEUCEL vs CIMETIDINE
CILTACABTAGENE AUTOLEUCEL vs CIMZIA
CILTACABTAGENE AUTOLEUCEL vs CINACALCET
CILTACABTAGENE AUTOLEUCEL vs CINNARIZINE
CILTACABTAGENE AUTOLEUCEL vs CINRYZE